ScreenerHero

XENE Xenon Pharmaceuticals Inc.

NAS · US · Healthcare · Biotechnology · xenon-pharma.com
36.41USD-0.44%Mkt Cap: 3.53B $P/E: —

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.53B USD
Enterprise Value2.62B USD
Revenue (TTM)0 USD
Gross Profit-352.48M USD
Net Income (TTM)-345.91M USD
Revenue/Share0.00 USD
Last Price36.41 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees358
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.76
PEG—
EV/EBITDA-5.96
EV/Revenue—
P/SInfinity
P/B2.85
EPS (TTM)-4.74
EPS (Forward)-4.71
52W Range
35.752% of range72.66
52W High72.66 USD
52W Low35.75 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-4612.13%
ROE-59.46%
ROA-54.63%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-279.12M USD
CapEx (TTM)799.00K USD
FCF Margin—
FCF Yield-5.77%
Net Debt-924.27M USD
Net Debt/EBITDA2.10
Balance Sheet
Debt/Equity0.01
Current Ratio21.02
Quick Ratio20.71
Book Value/Sh12.84 USD
Cash/Share9.61 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)73.37 USD
Upside (mean)+101.5%
Target Range46.00 USD – 97.00 USD
46.00+101.5% to mean97.00
# Analysts18
Ownership
Shares Out.96.84M
Float90.90M
Insiders0.16%
Institutions107.37%
Short Interest
Short Ratio10.3d
Short % Float6.66%
Short % Out.6.66%
Shares Short6.44M
Short (prev mo.)5.67M
Technical
SMA 5055.87 (-34.8%)
SMA 20053.07 (-31.4%)
Beta0.60
S&P 52W Chg15.78%
Avg Vol (30d)1.98M
Avg Vol (10d)2.61M
Technical Indicators
RSI (14)21.4
MACD-6.1513
MACD Signal-5.9938
MACD Hist.-0.1575
BB Upper65.61 USD
BB Middle44.96 USD
BB Lower24.32 USD
BB Width91.84%
ATR (14)2.245 USD
Vol Ratio (20d)0.77x